Novel methods for targeting cancer stem cells

Abstract

The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.

1 - 30 . (canceled) 
     
     
         31 . A method of treating a cancer in a human subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure of 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the compound is administered to the subject at a dose sufficient to achieve a blood concentration of the compound in the subject of at least 1.0 μM or above for at least two hours, and wherein the blood concentration of the compound in the subject is substantially cleared within at most 24 hours. 
     
     
         32 . The method of  claim 31 , wherein the compound is administered to the subject at a dose sufficient to achieve a blood concentration of the compound in the subject selected from the group consisting of at least 1.6 μM, at least 2.0 μM and at least 3.0 μM for at least two hours. 
     
     
         33 . The method of  claim 31 , wherein the compound is administered to the subject at a dose sufficient to achieve a blood concentration of the compound in the subject selected from the group consisting of at least 1.0 μM, at least 1.6 μM, at least 2.0 p.M and at least 3.0 μM for at least four hours. 
     
     
         34 . The method of  claim 31 , wherein the compound is administered to the subject at a dose sufficient to achieve an area under the curve in 24 hours (AUC 0-24 hr ) at least about 2 μM*hr to about 500 μM*hr, from about 10 μM*hr to about 300 μM*hr, from about 15 μ*hr to about 200 M*hr, about 20 μM*hr to about 100 μM*hr, or about 20 μM*hr to about 80 μM*hr. 
     
     
         35 . The method of  claim 31 , wherein the compound is administered to the subject at a dose sufficient to achieve an area under the curve in 24 hours (AUC 0-24 hr ) at least about 20 μM*hr to about 80 μM*hr, or about 30 μM*hr to about 60 μM*hr.